In the STEP-HFpEF trial, semaglutide use in obese heart failure patients with preserved LVEF was associated with a significant reduction in CRP levels, indicating a potential decrease in inflammation, a key factor in the development and progression of HFpEF [15]. This evidence concerns the gene CRP and heart failure.